Eli Lilly and Company (BIT:1LLY)

Market Cap	663.31B
Revenue (ttm)	43.51B
Net Income (ttm)	10.23B
Shares Out	n/a
EPS (ttm)	11.31
PE Ratio	64.85
Forward PE	n/a
Dividend	5.07 (0.69%)
Ex-Dividend Date	Feb 13, 2025

Volume	2,048
Average Volume	484
Open	649.70
Previous Close	658.20
Day's Range	644.10 - 754.00
52-Week Range	609.40 - 888.00
Beta	n/a
RSI	53.32
Earnings Date	May 1, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD